Abstract Clinical trials for acute heart failure syndromes (AHFS) have traditionally enrolled patients well after emergency department (ED) presentation. We hypothesized a large proportion of patients would undergo changes in clinical profiles during the first 24 h of hospitalization, and these changes would be associated with adverse events. We evaluated a prospective cohort of patients with clinical data available at ED presentation and 12-24 h after ED treatment for AHFS. Patients were categorized into distinct clinical profiles at these time points based on (1) systolic blood pressure: a-hypertensive ([160 mmHg); b-normotensive (100-159 mmHg); or c-hypotensive (\100 mmHg); (2) moderate-to-severe renal dysfunction (GFR B 60 ml/min/ 1.73 m 2 ); and (3) presence of troponin positivity. A composite outcome of 30-day cardiovascular events was determined by phone follow-up. In the 370 patients still hospitalized with data available at the 12-24 h time point, 196 (53.0%) had changed their clinical profiles, with 117 (59.7%) improving and 79 (40.3%) worsening. The composite 30-day event rate was 16.9%. Patients whose clinical profile started and stayed abnormal had a significantly greater proportion of events than those who started and stayed normal (26.1% vs. 11.3%; P = 0.03). Patients with abnormal clinical profiles at presentation that remain abnormal throughout the first 12-24 h of hospitalization are at increased risk of 30-day adverse events. Future clinical trials may need to consider targeting these patients, as they may be the most likely to benefit from experimental therapy.
Introduction
Clinical trials in patients with acute heart failure syndromes (AHFS) have been universally disappointing. Only one trial (VMAC) has resulted in the Food and Drug Administration (FDA) clearing a new therapy (nesiritide) for use in AHFS [1] . However, questions about nesiritide's safety and overly conservative dosing of nitroglycerin in the trial's standard care arm raised doubt about its role in AHFS [1] [2] [3] . While ASCEND-HF demonstrated nesiritide's safety, it did not demonstrate efficacy based on the primary endpoint [4] . This is consistent with other neutral therapeutic trials and, despite strong evidence of disease heterogeneity and concerns over confounding due to standard care, AHFS trials have largely not changed their approach. Patients continue to be enrolled long after their emergency department (ED) stay, when the majority have experienced significant improvement in dyspnea and a subset have already experienced adverse events that may be related to early therapy [5] [6] [7] [8] . The barrier preventing early enrollment has traditionally been the inability to enroll patients early in their ED course at the time of or prior to initial therapy. However, with the advent of strong alliances between emergency medicine and cardiology, this barrier has been largely overcome [9, 10] .
Recent clinical trial results suggest early enrollment and targeted therapy may result in improved outcomes in ED patients with AHFS. In a Phase II study of Relaxin, 234 patients with moderate renal dysfunction were randomized to standard care plus a 48-h infusion of placebo or Relaxin [11] . Patient were enrolled a median of 6.6 h from presentation, which is much earlier than other randomized AHFS trials. This early enrollment may have contributed to the observed dyspnea improvement and blood pressure control seen in treated patients at 6, 12, and 24 h after therapy, as well as the reduced number of cardiovascular events at day 60 [11] . Similar results were seen in ASCEND-HF, where patients enrolled less than 15.5 h from presentation had significantly less dyspnea at 6 h after drug initiation than those who were enrolled after 15.5 h (P = 0.008) [4] . Finally, a prospective trial has recently suggested an approach using high-dose nitroglycerin in ED patients with AHFS and hypertension is safe and efficacious [12] . This raises the possibility that when studying patients who receive experimental therapy early in their clinical course, at a time when standard therapy is normally administered, different results will be seen than when enrolling patients much later in their clinical course. Such differing treatment effects may arise from: (1) an interaction between initial standard and subsequent experimental therapy; or (2) a change in clinical characteristics resulting from early non-experimental treatment, with a subsequent change in likelihood of responding to therapy in the expected manner. Importantly, enrolling patients earlier and targeting those who are likely to not respond to standard therapy, and benefit most from experimental therapy, is crucial to improving our success rate in current clinical trials.
Patients who are enrolled in clinical trials 12-24 h after initial therapy are exposed to experimental therapy that targets their profile at the time of recruitment, but this is not necessarily the same as their profile at ED presentation. For example, a patient who was hypertensive with normal renal function at ED presentation may be relatively normotensive with renal dysfunction 12-24 h later. While this subject may have been excluded due to renal dysfunction at the time of enrollment, they would have been an ideal candidate for inclusion at ED presentation, because they would represent a subject who would have subsequently failed to respond safely to initial therapy.
Three prognostic variables readily available at ED presentation, which have been associated with patients who fail to respond safely to initial therapy, include systolic blood pressure, renal function, and troponin release [13] [14] [15] [16] [17] . The impact of ED therapy on these variables, and, more importantly, how these variable changes may influence subsequent treatment response, has not been well studied in a prospective manner that begins with ED enrollment. We hypothesize that patients who present to the ED with AHFS have initial clinical profiles that change substantially over the first 12-24 h after initial therapy. We further hypothesize that changes in these clinical profiles will be associated with the risk of adverse events.
Methods
This was a secondary analysis of data from a large, prospective observational cohort study conducted at the time of ED presentation in patients with AHFS [10] . It was approved by institutional review boards at each site, and each patient provided written, informed consent.
Setting and selection of subjects
In the cohort study, ED patients with signs and symptoms of AHFS presenting to four EDs, two in Nashville, Tennessee and two in Cincinnati, Ohio, were approached for enrollment and consent. Patients were approached for enrollment at the time of ED evaluations. All EDs were staffed by physicians from The University of Cincinnati or Vanderbilt University. This cohort represents a socioeconomically and demographically diverse group of subjects. Patients at Vanderbilt University Medical Center represent a highly educated, tertiary care cohort where 55% are female and a predominantly bi-racial population (approximately 60% white and 30% black). The Veterans Administration Tennessee Valley Healthcare System serves care to veterans predominantly in Middle Tennessee. Their patients seen in the ED are almost entirely male with an average age of 70. Cincinnati's University Hospital is an urban, tertiary care, teaching hospital, with a substantial indigent patient population. The ED population is bi-racial with both black and white patients; there is a mix of self-pay, insured, and Medicare and Medicaid patients. Cincinnati's Jewish Hospital is a community hospital that serves a largely white, higher socioeconomic status, insured population.
Study assistants and research coordinators, trained in patient identification, recruitment, and data collection, prospectively gather data during the participant's ED and hospital course. The study assistants approach the patient shortly after ED evaluation and then follow the patient during their inpatient stay. In addition to clinical presentation and post-treatment variables, medications administered during the first 96 h are also tracked using the nurses' medication administration record. Patients were treated and dispositioned at the discretion of the emergency medicine and inpatient physician.
To be eligible for this analysis, patients had to: (1) have AHFS recorded as either a primary or secondary diagnosis by the treating ED physician and (2) have received diuretic or vasodilator treatment for AHFS within 3 h of ED presentation. Treating physicians make their AHFS diagnosis based on data routinely available in the ED, which typically includes history and physical examination, an electrocardiogram (ECG), chest radiography, and results from serum chemistries, renal function, and b-type natriuretic peptide testing.
Data collection and processing
The study team records clinical variables upon ED presentation, and at 12-24, and 72-96 h after ED treatment. Vital signs and urine output are routinely recorded every 2-4 h in the ED and on the hospital floor, and often hourly in the ICU. Laboratory parameters are ordered on a daily basis in the majority of patients. However, patients also have blood drawn for the study if laboratory tests are not run as part of routine care. The cardiac troponin assay utilized for the study was the Abbott i-STAT, which has a 99th percentile reference limit of 0.08 lg/l [18] . [19, 20] .
Patients' clinical profiles were categorized as being initially normal or abnormal. Normal was defined as the absence of TNP, MRD, hypertension, or hypotension. Presence of one or more of those characteristics at baseline resulted in categorization as abnormal. Patients were then re-categorized based on the presence or absence of these characteristics at the 12-24 h point, with patients falling into four primary categories: (1) started abnormal and stayed abnormal; (2) started abnormal and became normal; (3) started normal and stayed normal; (4) started normal and became abnormal.
A composite 30-day event was used as the primary outcome measure for this analysis. An event comprised as follows: (1) an unscheduled ED revisit or rehospitalization for AHFS, (2) ACS, (3) percutaneous coronary intervention or coronary artery bypass grafting, (4) death, (5) defibrillation, (6) intubation, or (7) cardiopulmonary resuscitation. These events were determined by study investigators who performed telephone follow-up at 5-and 30-days after their ED presentation and confirmed events in the medical record; follow-up was conducted in person for hospitalized patients.
Statistical analysis
The sample was described using median and range for continuous variables and frequencies and percents for categorical variables. Chi-squared tests were used to compare categorical variables between groups. Where 95% confidence intervals (95CI) for proportions are given, these were computed using the score method with continuity correction. This analysis was largely descriptive in nature and was not powered to look at a comprehensive multivariable analysis. Analyses were conducted using SPSS v18.0 (SPSS Inc., Chicago, IL).
Results
Of the 455 patients available for analysis, the median age was 65 years, 56% were Caucasian, and 60% were male (Table 1) . Of these patients, 359 (78.9%) had a primary diagnosis of AHFS and 96 (21.1%) had a secondary diagnosis of AHFS. A primary diagnosis of NSTEMI occurred in 8 (1.8%), STEMI in 0 (0%), and 1 (0.2%) with a ventricular arrhythmia. There were no deaths in the ED and 11 (2.4%) discharged directly from the ED. Hypertension and pre-existing heart failure were common, and beta-blockers and diuretics were used frequently. Median systolic blood pressure at presentation was 147 mmHg. The majority of patients had an initial blood pressure in the normotensive (270, 59.3%) or hypertensive (174, 38.2%) range. The median BNP was 805 pg/ml, and congestion on chest radiograph and on clinical exam was common.
Initial clinical profiles
All 455 patients were categorized into one of twelve distinct, baseline clinical profiles ( The 30-day event rate in those with data available at 12-24 h was 16.9%. All but 4 of the patients were discharged from their index stay by the 30-day follow-up. Of the 41 patients admitted to the intensive care unit, 4 (9.8%) experienced a 30-day event. In the overall cohort, 45 (10.0%) had an unscheduled ED visit for AHFS, 52 (11.0%) were hospitalized for AHFS, 2 (0.4%) had sudden death with defibrillation or CPR, 2 (0.4%) had ACS, 4 (1.0%) had PCI, 4 (1.0%) were intubated, 3 (1.0%) received coronary artery bypass grafting, and 15 (3.3%) had all-cause death.
Patients who had worsening of their clinical profile had a slightly greater proportion of adverse events than those with improved clinical profiles (20.5% vs. 17.6%; P = 0.7). Importantly, patients who started with an abnormal clinical profile and stayed abnormal had a significantly greater proportion of events than those who started normal and stayed normal (26.1% vs. 11.3%; P = 0.03).
Discussion
Based on this secondary analysis, over 50% of patients treated in the ED for AHFS undergo changes in their clinical profiles within the first 24 h of therapy. Approximately 40% of these changes resulted in the development of MRD or TNP, identifying a cohort of patients who failed to safely respond to initial therapy. Conversely, nearly 60% had clinical improvement, suggesting initial therapy was beneficial in this subset. Adverse event rates were high overall, indicating that such clinical changes may be harmful for some patients, while outcomes in others may be more influenced by comorbidities or precipitants [21] . TNP troponin positivity MRD moderate-to-severe renal dysfunction Our findings suggest that those patients whose profiles started abnormal and stayed abnormal are significantly more likely to have an adverse event compared to those who started and stayed normal. However, while those patients who had worsening of their clinical profile had a greater number of events than those who improved (20.5% vs. 17.6%), this was not statistically significant. This represents a total of 37 patients, and perhaps in a larger cohort, this absolute difference of 2.9% would be clinically significant.
We chose renal function, blood pressure, and troponin release a priori not only because of their prognostic significance but also because they are readily available at ED presentation. Previous studies have already demonstrated the magnitude of changes in dyspnea over time and indicate that the earlier treatment is initiated, the greater and more rapid the dyspnea improvement [4, 11, 22] . However, the findings in our current study also suggest that early treatment is also associated with changes in clinical characteristics in a significant proportion of patients. Further, these changes, or lack thereof, appear to be associated with a patient's clinical course. Together, these results imply we need to regard not only a patient's current clinical profile at the time of enrollment but also their clinical profile when they presented to the ED. These findings may also have implications for clinical trial design. Our data suggest that 40% of patients may not respond safely to initial therapy, and targeting this group with experimental therapy to safely improve symptoms should be considered. If patients can be identified early, they may be eligible for enrollment in clinical trials that had previously excluded them when they were enrolled 12-24 h after initial therapy. Moreover, this would remove the spectrum bias toward excluding those patients who do not safely respond to standard therapy. For example, our data suggests those patients with persistent abnormal clinical profiles after initial therapy, who have an increased adverse event rate, may be good candidates for therapeutic trials. Importantly, these findings also suggest that exclusion from a trial because of an anticipated poor clinical course may be premature. In fact, these patients may be the cohort we want to enroll, as they are unlikely to respond to standard therapy but may respond preferentially to experimental therapy. Further, while some patients do develop worsening renal function during their hospital stay, others improve, and changes may only be transient and may not impact short-term clinical outcomes [15] . Further, patients who would currently be considered ineligible because of renal dysfunction or an elevated troponin could be enrolled Table 3 Changing AHFS phenotypes over the first 24 h of therapy
Phenotypic Characteristics 12-24 hours after ED Presentation
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Normotensive Hypertensive MRD-MRD+  MRD-MRD+  MRD-MRD+   TNP-TNP+ TNP-TNP+ TNP-TNP+ TNP-TNP+ TNP-TNP+ TNP-TNP+ to receive therapy aimed at minimizing on-going renal or cardiac injury, and the increased adverse clinical events that occur if improvement is not apparent. Such individualized therapy is a critical next step as we tailor treatment to those patients who respond poorly to traditional management strategies or show signs of organ injury and dysfunction. However, in order to safely enroll patients early in clinical trials, we need to better understand the interaction between their phenotypic presentation and underlying pathophysiology, as well as how this interaction impacts their response to therapy and clinical trajectory. This identification process starts with categorizing patients based on several characteristics, such as initial disease severity, comorbidities, precipitants, and perhaps novel biomarkers [21] . Once categorized, patients can then be followed to determine whether their allocated treatment results in end-organ dysfunction or an adverse event. To achieve this, further examination of the categorization process is needed with a specific focus on those variables that can rapidly and accurately help differentiate high-and low-risk patients.
Individualized treatment in AHFS randomized trials has been traditionally problematic, but targeting this population with a single therapy has not been successful to date. Furthermore, a study design that focuses on a single therapy does not readily generalize to the typical ED patient with AHFS and multiple comorbidities. As our findings suggest, heterogeneity defines this patient population, an issue that is compounded by the fact that in many, the initial clinical profile will change soon after presentation. Studies that match specific patient profiles with individualized treatment approaches are needed, and contemporary clinical trial approaches may facilitate this. For example, Bayesian adaptive trial design provides us with a unique opportunity to study multiple patient profiles with a variety of treatment approaches, while keeping the sample size reasonable [23] . Under this design, as the trial progresses, patient profiles and treatments may be removed (or added), both for futility and efficacy, until all modes of therapy have been adequately tested across the patient profiles. Although such a trial does require significant upfront planning and collaboration by the investigative team, including emergency physicians, heart failure physicians, and biostatisticians, the potential upside is tremendous.
Limitations
While our results suggest that a large proportion of patient's profiles changed during the first 12-24 h of an acute presentation, there are some noteworthy limitations worth discussing. First, significant adverse events after the 30-day time period were not recorded. However, it is often difficult to determine the association between the index visit and events that occur 60-90 days later. Secondly, as an observational study, treatment was not controlled and has also not been considered in analysis; understanding the association between treatment and outcomes was not the goal of this analysis. Subsequent studies that aim to examine these profiles in detail should consider the relationship between initial treatment and subsequent endpoints. Further, we do not have the exact date of the subjects' events, so it is hard to determine whether the subjects experienced events while hospitalized or as an outpatient. We do know that approximately 75% of patients were discharged within 5 days and 6% of patients had events at 5 days. Because this study was observational, there is a possibility that differences in outpatient management, patient behaviors, and the protective effect of hospitalization could have confounded our findings.
While we utilized strict definitions of moderate-tosevere renal dysfunction and TNP, troponin rise in AHFS can occur for many reasons and an elevated troponin alone may not be indicative of ACS. In particular, troponin release may be an on-going process in patients with more severe heart failure and thus independent of cardiac injury due to microvascular or macrovascular to coronary artery disease [24] . Nonetheless, it is clear that regardless of mechanism, patients with AHFS and an elevated troponin have a far worse prognosis [25] . Finally, the limited sample size prohibits definitive conclusions about whether the individual components of clinical profile (i.e., TNP, renal dysfunction, or hemodynamics) contributed to 30-day events with an equivalent or differential effect. This was a descriptive paper about three readily-available ED variables and not a comprehensive analysis about all variables available during the first 24 h of hospital admission. Finally, our subjects were enrolled early in their clinical course, within 3 hours of initial ED evaluation and treatment. While there may be a discrepancy in ED and hospital discharge diagnosis in 10-15% of patients, our data were collected prospectively during a time period that is often overlooked and underrepresented in registries and clinical trials.
Conclusion
Heterogeneity defines ED patients with AHFS, an issue that is compounded by the fact that in over 50% of these patients, their initial clinical profile will change within the first 12-24 h of acute presentation. Many of these changes are related to development of MRD or TNP. Patients with abnormal clinical profiles at presentation that remain abnormal throughout the first 12-24 h of hospitalization are at significantly higher risk of 30-day adverse events than those whose profiles remain normal during this time period. Future clinical trials may need to consider targeting these patients, as they may be the most likely to benefit from experimental therapy.
